EcoDrugPlus

Polo Like Kinase 4

Ensembl ID : ENSXETG00000022522
Gene Symbol: PLK4
16 Enzyme and pathways 5 View Cross-references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSXETG00000022610
Gene Symbol: PARP1
26 Enzyme and pathways 5 View Cross-references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSXETG00000001748
Gene Symbol: PARP2
13 Enzyme and pathways 5 View Cross-references
185 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSXETG00000000087
Gene Symbol: PARP3
5 View Cross-references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Porcupine O-Acyltransferase

Ensembl ID : ENSXETG00000007920
Gene Symbol: PORCN
5 View Cross-references
266 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSXETG00000018041
Gene Symbol: KCNMA1
6 Enzyme and pathways 5 View Cross-references
323 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Channel, Calcium Activated Intermediate/small Conductance Subfamily N Alpha, Member 4

Ensembl ID : ENSXETG00000004088
Gene Symbol: KCNN4
3 Enzyme and pathways 5 View Cross-references
187 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Channel, Two Pore Domain Subfamily K, Member 2

Ensembl ID : ENSXETG00000023120
Gene Symbol: KCNK2
7 Enzyme and pathways 5 View Cross-references
282 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Channel, Two Pore Domain Subfamily K, Member 9

Ensembl ID : ENSXETG00000038355
Gene Symbol: KCNK9
7 Enzyme and pathways 5 View Cross-references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Channel, Voltage Gated Kqt-Like Subfamily Q, Member 2

Ensembl ID : ENSXETG00000032009
Gene Symbol: KCNQ2
5 View Cross-references
248 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Channel, Voltage Gated Kqt-Like Subfamily Q, Member 5

Ensembl ID : ENSXETG00000031377
Gene Symbol: KCNQ5
3 Enzyme and pathways 5 View Cross-references
278 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Channel, Voltage Gated Shal Related Subfamily D, Member 3

Ensembl ID : ENSXETG00000013577
Gene Symbol: KCND3
6 Enzyme and pathways 5 View Cross-references
259 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).